Markets / Industries / Healthcare & Hospitals
Industry view · Healthcare & Hospitals
Healthcare AI spend nearly tripled to $1.4 billion in 2025, with providers absorbing 75% of it, while the FDA's cumulative tally of authorized AI-enabled devices hit 1,451. The money is flowing to production, not pilots — and to the administrative seams of medicine before its clinical core.
01 · The thesis
The decisive fact of 2025 is that healthcare, long mocked as a digital laggard, now adopts AI 2.2x faster than the broader economy, with 22% of organizations running domain-specific tools versus 9% economy-wide (Menlo Ventures, survey of 700+ executives). But the spend is concentrated where ROI is unambiguous and patient risk is low: ambient documentation ($600M, +2.4x YoY) and coding-and-billing automation ($450M). Hospitals, squeezed by thin margins and staffing shortages, are the buyers; payers, wary of compliance exposure, lag with just 5% of spend and lengthening buying cycles.
The clinical frontier moves on a different clock. Radiology dominates the FDA's authorizations — 1,104 of 1,451 devices, 76% of the total — because images are structured and triage is bounded. Yet the heaviest concentration of capital and hype, from OpenEvidence's $12B valuation to Abridge's $5.3B, sits in workflow and decision-support, not autonomous diagnosis. The gap between adoption breadth (most hospitals run AI *somewhere*) and clinical depth (under 20% embed it in core diagnosis) is the central tension of the cycle.
AlphaFold's commercial spinout Isomorphic Labs raised $600M (March 2025) then a $2.1B Series B, betting AI can compress preclinical timelines.
Radiology accounts for ~75% of 2025's 295 new FDA AI clearances; AI triage for stroke and cancer is now standard procurement.
OpenEvidence reports use by 40%+ of US physicians, processing a month of 2024 volume in a single day — but as assistive copilot, not decision-maker.
The scribe category hit $600M revenue in 2025; physicians spend ~1 hour documenting per 5 hours of care, and tools cut that >50%.
Optum's AI prior-auth eliminates 45% of manual touches at 96% first-pass approval, but utilization-review AI faces scrutiny over denials.
02 · Public players & exposure
We plot the listed players on two editorial axes — how exposed each is to AI disruption, against how ready its data, brand and position are to be the answer. The figures in the table are sourced; the placement is our read.
| Company | Stance | The sourced fact |
|---|---|---|
| UnitedHealth (Optum)UNH | Scaled incumbent | UnitedHealth disclosed 1,000+ AI use cases including claims, and AI now routes 26M consumer calls annually; Optum's AI prior-auth cuts 45% of manual touches (WSJ, May 2025; Optum, Feb 2026). |
| Tempus AITEM | AI-native diagnostics | Full-year 2025 revenue of ~$1.27B, up ~83% YoY, with diagnostics up ~111% and data licensing up ~38%; first positive adjusted EBITDA in Q3 2025 (Tempus, Feb 2026). |
| GE HealthCareGEHC | Imaging AI leader | Topped the FDA's AI-enabled device authorization list four years running, holding the most radiology AI authorizations at 120 including acquisitions (Imaging Wire, March 2026). |
| Microsoft (Dragon/DAX)MSFT | Platform incumbent | 400+ healthcare organizations use DAX/Dragon Copilot, saving clinicians 5+ minutes per encounter; built on the $19.7B Nuance acquisition (Becker's / Microsoft, 2025). |
| HCA HealthcareHCA | Provider adopter | Deploying AI for nurse staffing, sepsis-style patient-safety monitoring and ambient ED documentation across its ~50,000-bed network (AHA, Oct 2025). |
| OpenEvidencepvt | Decision-support breakout | Reached a $12B valuation in January 2026, more than tripling inside a year, and used by 40%+ of US physicians; raised ~$700M from GV, Nvidia, Sequoia, Mayo Clinic (CNBC, Jan 2026). |
| Abridgepvt | Scribe leader | Raised a $300M Series E in June 2025 at a $5.3B valuation, roughly doubling in four months; Best in KLAS for Ambient AI 2025 and 2026 (TechCrunch / KLAS). |
| Ambience Healthcarepvt | Scribe challenger | $243M Series C in July 2025 at a $1.25B valuation; used by 40+ health systems and reports ~45% less charting time across deployments (STAT, July 2025). |
| Isomorphic Labspvt | AI drug design | Raised $600M in its first external round (March 2025) then a $2.1B Series B led by Thrive, with no approved drug yet — a long-horizon bet (Isomorphic Labs / BioSpace). |
| Oracle (Cerner Health)ORCL | EHR incumbent at risk | Pushing its Clinical AI Agent across the Oracle Health EHR base, but defending share against Epic-aligned AI partners and ambient-scribe disruptors (Oracle Health, 2025). |
03 · The two clocks
Three timing dynamics that govern which bets pay off
Adoption velocity has inverted the old story. Health-system AI buying cycles compressed from 8.0 to 6.6 months and outpatient from 6.0 to 4.7 months, while payer cycles *lengthened* to 11.3 months as insurers weigh compliance risk (Menlo Ventures, 2025). Capital follows the fast buyers: providers command 75% of the $1.4B spend.
Regulatory throughput is accelerating but uneven. The FDA cleared a record 295 AI/ML devices in 2025 (up from 253 in 2024), with a 142-day median clearance time, yet 76% remain radiology — a sign clinical AI still wins approval mostly where outputs are visual and bounded (Innolitics / FDA, 2025).
Valuations are running ahead of revenue. The ambient-scribe category has drawn over $4.8B in funding since 2019 against ~$600M of 2025 revenue, and OpenEvidence reached $12B in under a year — a velocity that prices in a future of agentic clinical workflows that has not yet arrived (PitchBook / CNBC).
04 · Private flagships
The companies attacking this industry AI-first, with disclosed funding where available:
'ChatGPT for doctors' trained only on peer-reviewed literature (NEJM, JAMA), used by 40%+ of US physicians at the point of care.
Captures clinician-patient conversations into structured, billable Epic notes; back-to-back Best in KLAS for Ambient AI.
Runs scribing, real-time coding and documentation integrity from one ambient recording across 40+ health systems.
AI-enabled genomic testing plus a data-licensing business; building a multimodal oncology foundation model with AstraZeneca.
AI detection-and-coordination suites for stroke, vascular, cardiac and pulmonary care, alerting specialists in real time.
DeepMind spinout applying AlphaFold-lineage models to drug design across multiple therapeutic areas, pre-clinic.
05 · Signals
A Series D led by Thrive and DST cements it as the most valuable healthcare AI company, signaling investor conviction in vertical clinical AI (CNBC).
Humata-powered Digital Auth Complete claims 96% first-pass approval and 80% efficiency gains, pushing payer automation toward real-time decisions (Optum).
AI-diagnostics revenue up ~111% and a first positive adjusted EBITDA quarter validate that diagnostic AI can carry a public-market P&L (Tempus).
Up from 253 in 2024 across 221 manufacturers, with radiology at 76% — the regulatory pipeline is widening but still imaging-skewed (Innolitics/FDA).
A cloud AI platform for fetal and maternal monitoring shows incumbents and providers co-developing clinical AI, not just buying scribes (AHA).
06 · The exposure read
AI rewards clean, structured advantage and punishes friction. The line runs through who owns the data, the brand and the customer — and who is merely a step the technology can route around.
Sources
MarketsandMarkets — AI in Healthcare Market ($25.88B in 2025) · Menlo Ventures — 2025: The State of AI in Healthcare · The Imaging Wire — FDA 1,451 AI devices; GE HealthCare 120 lead · Innolitics — 2025 Year in Review: 295 AI/ML FDA clearances · Dialog Health — AI in Healthcare Statistics (physician adoption) · Klover.ai — UnitedHealth Group AI strategy (1,000 use cases, 26M calls) · Optum — AI-powered digital prior authorization (96% first-pass) · Tempus AI — Preliminary Q4 and Full Year 2025 Results ($1.27B revenue) · CNBC — OpenEvidence doubles valuation to $12B · TechCrunch — OpenEvidence hits $12B; ~$700M raised in under a year · FierceHealthcare — Abridge $300M Series E at $5.3B valuation · STAT — Ambience mega-round ($243M Series C, $1.25B) · PitchBook — Healthtech AI Scribes ($4.8B raised since 2019; 40+ startups) · Becker's — 400+ orgs adopt Microsoft DAX Copilot